Compare Nano Dimension Ltd - ADR (NNDM) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nano Dimension Ltd - ADR vs Nuvalent Inc — how do they compare? Nano Dimension Ltd - ADR trades at $1.49 (market cap $322.08M), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Nuvalent Inc is far larger — about 30.5× Nano Dimension Ltd - ADR's market cap, and Nuvalent Inc is trading nearer its 52-week high, Nano Dimension Ltd - ADR nearer its low. Which is the better fit depends on your goals.
| NNDM | NUVL | |
|---|---|---|
Market Cap | $322.08M | $9.81B |
Sector | Technology | Technology |
52-Week High | $2.14 | $123.96 |
52-Week Low | $1.21 | $72.16 |
Enterprise Value | -$87.26M | $8.52B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
